Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

SimBioSys® Welcomes Dr. Barry Rosen as Chief Medical Officer After Securing FDA Clearance for TumorSight™ Precision Medicine Platform

NextEdge Admin

22 Dec 2023

2 min 43 sec

SimBioSys, a groundbreaking TechBio company at the forefront of spatial biophysics and artificial intelligence (AI) in precision medicine for cancer, is excited to announce the appointment of Dr. Barry Rosen as its Chief Medical Officer. Dr. Rosen, a highly regarded breast surgical oncologist with over 25 years of clinical expertise, brings extensive experience from prestigious organizations such as the American Society of Breast Surgeons and the National Consortium of Breast Centers.

This strategic move aligns with SimBioSys’ achievement of FDA clearance for its digital precision medicine platform, TumorSight™, marking a pivotal moment for the company.

Tushar Pandey, CEO of SimBioSys, highlighted the significance of Dr. Rosen’s appointment, acknowledging his expertise as integral to advancing technologies, gaining insights into tumor biology, and addressing real-world challenges in the cancer community.

The FDA cleared application TumorSight™ is a cloud-based digital precision medicine platform intended to support the end-to-end patient journey.It utilizes standard-of-care medical imaging (DCE MRI) to create stunning 3D spatial visualizations, providing clinicians and patients with a more comprehensive understanding of cancer and treatment options. AI is employed to automatically segment the tumor and surrounding tissue, displaying the 3D visualization, and offering key insights such as tumor volume, tumor-to-breast volume, and tumor distance to anatomical structures.

With breast cancer being the most prevalent cancer among women in the U.S., SimBioSys aims to address the critical need for tools that seamlessly integrate into clinicians’ workflows. Recent findings presented at the 2023 San Antonio Breast Cancer Symposium highlighted the positive impact of TumorSight™ Viz on treatment planning and patient consultations, with high percentages of clinicians and breast cancer patient opinion leaders acknowledging its value and importance.